doi: 10.1210/jcem.74.6.1375600 35 ChenJWHojlundKBeck-NielsenHSandahl ChristiansenJOrskovHFrystykJ
The primary endpoint of IIH EVOLVE will assess efficacy of Presendin to reduce intracranial pressure (ICP) over 24 weeks compared to placebo
The most frequently reported side effects are nausea, vomiting, diarrhoea, and mild hypoglycaemia (when used with certain other medications)
Fill out the form below for a confidential consultation, and our admissions specialists will reach out to discuss our specialized programs and verify your insurance coverage
Weight loss experts emphasize the need for a holistic approach combining medication with lifestyle changes for effective weight loss, Newsday has reported
Participants who completed VESPER-1 were eligible to enroll in an exploratory open-label extension that evaluated higher weekly dosing (1.6 mg, 2.4 mg) and less frequent dosing (every other week and monthly)